The ONE Forum 2024 on-demand sessions for transplant centers
Gain valuable insights for decision-making
View on-demand breakout sessions from The ONE Forum® by NMDPSM. These breakout sessions offer information for transplant centers.
Advancements in Donor Selection: Best Practices in Choosing a Mismatched Unrelated Donor
Delve into the complexities of selecting mismatched unrelated donors (MMUD) for hematopoietic cell transplantation (HCT). Experts share critical factors that influence the decision-making process when choosing or prioritizing MMUDs.
You'll receive a comprehensive overview of the latest best practices and where there are currently knowledge gaps in the field. Gain valuable insights into optimizing donor selection to enhance transplant outcomes for your patients, even in the context of HLA mismatches.
Recent Research Highlights in Health Equity
Explore the current state of health equity within the HCT and cell therapy field. You'll receive an overview of Medicaid coverage for HCT and CAR-T therapy based on up-to-date research from the ASTCT-NMDP ACCESS Initiative. The panel delves into real-world data from one transplant center that shows how expanding donor searches to mismatched donors leads to a donor for all.
In addition, you'll learn about the HCT ecosystem for older adults and identify opportunities for improvement at your own center. Deepen your understanding and contribute to advancing health equity in HCT and cell therapy.
Genetic Insights: Impact of Genetics on Hematopoietic Cell Transplant Recipients and Donors
Genetics can impact a patient's diagnosis, treatment and disease monitoring before and after HCT. However, post-transplant genetic testing can have implications for both donors and patients when a genetic finding may be of potential donor origin.
Get a better understanding of the critical role genetics have in optimizing treatment strategies and enhancing transplant care, the importance of ongoing monitoring, and how NMDP implemented a formal reporting process for post-transplant genetic findings.
Advancements in Donor Selection: Timely Selection of Donor Type
Gain insights into the pivotal findings from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1702 clinical trial, which revolutionizes the approach to donor selection by focusing on timely transplant strategies. The BMT CTN 1702 trial introduced a novel strategy to guide the selection process, categorizing patients into groups based on their likelihood of finding a fully matched donor.
Experts present the trial's key outcomes and discuss how transplant centers can operationalize these findings to better understand their search prognosis and make faster decisions on pivoting to alternative donors and optimize a patient's time to transplant.